Neuroprotection: challenges and opportunities

Area of Science:

• Neuroscience
• Pharmacology
• Neurology

Background:

• Pharmacological agents effectively limit secondary damage in animal models of central nervous system injury.
• Translating neuroprotective strategies from animal models to human clinical trials for stroke, head injury, and spinal cord injury has yielded disappointing results.
• Numerous conceptual and methodological issues hinder the clinical translation of experimental neuroprotection.

Purpose of the Study:

• To review critical problems and potential solutions in translating neuroprotective treatments for central nervous system injuries.
• To emphasize recent experimental and clinical work in neuroprotection.
• To provide cautious optimism for future clinical trials of neuroprotective agents.

Main Methods:

• Literature review of experimental and clinical studies on neuroprotection.
• Analysis of conceptual and methodological challenges in clinical translation.
• Emphasis on recent advancements in experimental approaches and clinical trial design.

Main Results:

• Despite established efficacy in animal models, neuroprotective agents have largely failed in human trials for neurological injuries.
• Key challenges include differences in injury models, treatment timing, and clinical trial methodologies.
• Recent modifications in experimental and clinical approaches offer renewed hope for neuroprotection.

Conclusions:

• Translating neuroprotective therapies for central nervous system injuries remains a significant challenge.
• Addressing methodological and conceptual issues is crucial for successful clinical translation.
• Continued research and innovative trial designs may lead to effective neuroprotective treatments in the future.